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Summary
Recent studies have demonstrated that introduction of hTERT in combination with SV40 large T antigen (LT), small t antigen
(st), and H-rasV12 suffices to transform many primary human cells. In human mammary epithelial cells (HMECs) expressing
elevated c-Myc, activated H-Ras is dispensable for anchorage-independent growth. Using this system, we show that st
activates the PI3K pathway and that constitutive PI3K signaling substitutes for st in transformation. Moreover, using
constitutively active versions of Akt1 and Rac1, we show that these downstream pathways of PI3K synergize to achieve
anchorage-independent growth. At lower levels of c-myc expression, activated PI3K also replaces st to complement
H-rasV12 and LT and confers both soft agar growth and tumorigenicity. However, elevated c-myc expression cannot
replace H-rasV12 for tumorigenesis. These observations begin to define the pathways perturbed during the transformation
of HMECs.
Introduction teins act as GTP/GDP-regulated molecular switches that modu-
late signal transduction pathways controlling cell proliferation,
differentiation, and survival (Shields et al., 2000). Ras stimulatesCultured HMECs immortalized with hTERT provide an important
in vitro model system for studying the tumorigenic conversion multiple effector-mediated signaling pathways, including the
Raf-MEK-ERK, the phosphatidylinositol 3-kinase (PI3K), and theof HMECs. HMECs must bypass several barriers before they
become immortalized (Romanov et al., 2001). Soon after explan- RalGDS pathways. Ras function in oncogenic transformation
has been extensively studied; however, much of our under-tation, HMECs lose p16INK4A expression usually secondary to
promoter methylation (Foster et al., 1998). The introduction of standing of Ras transformation is derived from rodent cell sys-
tems. The Raf effector pathway has been shown to be a keyhTERT readily immortalizes such cells (Kiyono et al., 1998). We
previously showed that the serial introduction of the SV40 early mediator of Ras-transforming activity in rodent cell lines (Cowley
et al., 1994; Mansour et al., 1994). However, a recent reportregion and H-rasV12 sufficed to transform several types of
hTERT-immortalized human cells, including early passage indicated that Ras-activated signaling via the RalGDS pathway
plays a dominant role in the transformation of human cells inHMECs (Hahn et al., 1999; Elenbaas et al., 2001). We and others
subsequently demonstrated that both LT and st antigens are contrast to the central contribution of Raf signaling in rodent
cells (Hamad et al., 2002). Thus, although alterations of therequired for the transforming activity of the SV40 early region
(Yu et al., 2001; Hahn et al., 2002). Several groups have used pathways regulated by Ras play an important role in transforma-
tion, the relative contribution of each of these signaling path-other combinations of introduced genes to transform other hu-
man cells (Brookes et al., 2002; Seger et al., 2002; Lazarov et ways remains undefined.
The SV40 early region encodes at least two proteins throughal., 2002). These observations suggest that dysregulation of a
limited set of pathways governs the human cell transformation alternative splicing. One of these oncoproteins, the SV40 LT
antigen, binds to and inactivates, among other proteins, theand that further dissection of the signaling pathways perturbed
by these introduced genes will identify key steps in oncogenesis. p53 and retinoblastoma (pRB) tumor suppressors (Sullivan and
Pipas, 2002). Inactivation of these two tumor suppressor path-The ras gene is mutated in many human cancers. Ras pro-
S I G N I F I C A N C E
Studying the mechanisms used by DNA tumor viruses to transform mammalian cells has elucidated the identity and function of
many cellular pathways critical for the development of human cancers. The SV40 early region encodes two oncoproteins LT and st
that transform human cells. Although the actions of LT are well characterized, the pathways perturbed by st remain undefined. Here
we show that one critical target of st is the PI3K pathway. Activation of PI3K signaling functionally mimics the expression of st and
confers anchorage-independent growth and tumorigenicity. These human cells, which are dependent on activated alleles of PI3K
or Akt for their transforming behavior, will facilitate the testing of specific inhibitors of this oncogenic pathway.
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ways suffices to transform human cells in the presence of onco- age-independent growth. However, this combination fails to
permit HMEC to form tumors in animal hosts without the addi-genic H-Ras, hTERT, and a second oncoprotein from the SV40
early region, st. Although the role of st in human cell transforma- tional expression of H-rasV12. Since alterations in the pathways
governed by PI3K, Ras, and Myc are associated with humantion was not appreciated in initial studies of hTERT-immortalized
cells (Hahn et al., 1999; Elenbaas et al., 2001), st expression breast cancer, these observations provide an opportunity to
construct increasingly relevant models of human breast cancerwas subsequently shown to be a prerequisite for the oncogenic
conversion of human cells (Yu et al., 2001; Hahn et al., 2002). that will not only increase our understanding of malignant trans-
formation of breast epithelium but also provide new substratesReplacing the SV40 early region with human papillomavirus E6/
E7 oncoproteins failed to transform human fibroblasts (Morales for the discovery of novel therapeutics.
et al., 1999) and human keratinocytes (Yuan et al., 2002). The
additional expression of st in these cells, expressing either LT Results
or E6/E7, however, completed the transformation of such cells
(Hahn et al., 2002; Yuan et al., 2002). Indeed, these observations Anchorage-independent growth of late passage
HMEC-hTERT expressing SV40 LT and stconfirm earlier studies using SV40 mutants unable to produce
functional st, which showed that these mutants were defective To dissect further the pathways involved in the transformation of
HMECs, we obtained early and late passage HMECs. Consistentin the transformation of human fibroblasts (de Ronde et al.,
1989). This ability of st to cooperate in transformation depends with prior observations (Foster et al., 1998; Romanov et al.,
2001), these cells, which had bypassed an initial growth arrestupon its interaction with the PP2A family of serine-threonine
phosphatases (Pallas et al., 1990; Yang et al., 1991; Mungre et (termed M0), lack expression of p16INK4a (data not shown). We
immortalized early passage HMECs population doubling 20 (PDal., 1994; Hahn et al., 2002). Although several signaling path-
ways, including the MEK-ERK and PI3K/Akt pathways, are per- 20) through the introduction of hTERT and obtained commer-
cially available, late passage hTERT-immortalized HMECs atturbed by the interaction of st with PP2A (Sontag et al., 1993;
Yuan et al., 2002), the identity of the particular pathways in- PD 134, which maintain the phenotype and karyotype of normal
epithelial cells.volved in human cell transformation remains obscure and over-
laps with those perturbed by oncogenic Ras. To express SV40 T antigens in HMECs, we introduced either
the SV40 early region, which encodes both LT and st, or LTPI3Ks are heterodimers with a regulatory subunit, p85, and
a catalytic subunit, p110. The primary consequence of PI3K and st individually by retrovirus-mediated gene transfer (Figure
1A). We also generated cell lines that express H-rasV12 in com-activation is the conversion of phosphatidylinositol-4,5-diphos-
phate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) bination with these introduced genes and assessed the ability
of each of these cell lines to proliferate in an anchorage-indepen-in the plasma membrane, which then functions as a second
messenger to activate downstream pathways that involve Akt, dent fashion, a hallmark of in vitro transformation (Cifone and
Fidler, 1980). Surprisingly, expression of SV40 early region inRac1/Cdc42, and other proteins (Vanhaesebroeck et al., 2001).
Numerous studies have highlighted the importance of PI3K the absence of H-rasV12 sufficed to induce colony formation
in late passage HMECs-hTERT (Figure 1B). We found similarfunction in cell proliferation and transformation. Amplification
and aberrant activation of PI3K and Akt occur in breast and results when we introduced LT and st separately into late pas-
sage hTERT-immortalized HMECs (Figure 1B). Consistent withovarian cancers (Bellacosa et al., 1995; Shayesteh et al., 1999).
Moreover, PTEN, a negative regulator of the PI3K pathway, was previous observations (Elenbaas et al., 2001), early passage
HMECs expressing hTERT and the SV40 early region requiredoriginally isolated as a tumor suppressor gene in breast cancer
and glioblastomas, and has subsequently been implicated in the addition of H-rasV12 for anchorage-independent growth.
Moreover, expression of st alone in HMECs expressing hTERTmany types of human cancers (Li et al., 1997; Steck et al., 1999).
Together, these observations underscore the importance of failed to confer the ability to grow in an anchorage-independent
manner (data not shown). Thus, although late passage hTERT-PI3K signaling in malignant transformation.
The c-Myc oncoprotein is also frequently amplified or over- immortalized HMECs retain many morphological features of pri-
mary HMECs, such cells require fewer alterations to permitexpressed in naturally arising primary breast carcinomas (Escot
et al., 1986). In fact, deregulated expression of c-myc occurs anchorage-independent growth.
in a broad range of human cancers and is often associated with
aggressive, poorly differentiated phenotypes (Pelengaris et al., SV40 st enhances and prolongs EGF-induced
Akt phosphorylation2002). The c-myc protooncogene regulates diverse biological
processes, including cell proliferation, growth, and differentia- Although the interaction of st with PP2A is essential for the
transformation of human cells (Porras et al., 1996; Hahn et al.,tion (Dang, 1999). Recent studies with conditional transgenic
mouse models have shown that c-myc activation is required 2002), the signaling pathways regulated by this interaction and
necessary for human cell transformation remain undefined. Infor solid tumor maintenance (Pelengaris et al., 1999), and c-myc
inactivation results in tumor regression (Felsher and Bishop, addition, the presence of H-rasV12 adds considerable complex-
ity by activating multiple signaling pathways, many of which are1999). However, the role of c-myc in tumorigenesis remains
enigmatic. also PP2A targets. Thus, these late passage HMECs-hTERT
that do not require constitutively active Ras for anchorage-Here we show that introduction of LT and st suffices to
permit late passage HMEC-hTERT to grow in an anchorage- independent growth provided a system with which to study the
effects of st without the confounding effects of oncogenic Ras.independent manner. Exploiting this system, we further demon-
strate that activation of the PI3K pathway or activation of two Transient expression of st in mammalian cells activates
growth factor-stimulated signaling pathways involving the PI3Kdownstream target pathways of PI3K, in the presence of in-
creased expression of c-myc, replaces st and permits anchor- (Sontag et al., 1997; Garcia et al., 2000) and MEK-ERK pathways
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(Sontag et al., 1993; Ugi et al., 2002). To assess the effects of
st in HMECs on these two signaling pathways, we measured
the level of phosphorylation of Akt and ERK in HMECs-hTERT-
LT stably expressing st. Cells were starved in mammary epithe-
lial basal medium (MEBM) and stimulated with epidermal growth
factor (EGF). Cell lysates were analyzed by immunoblotting with
antibodies specific for activated Akt (phosphorylated at Ser473)
or activated ERK1/2 (phosphorylated at Thr202/Tyr204). The
expression of st did not alter basal levels of phospho-Akt or
phospho-ERK1/2 (Figures 2A and 2B). However, upon stimula-
tion with EGF, phospho-Akt levels were further enhanced by
2- to 3-fold in st-expressing cells (Figure 2A), whereas the phos-
pho-ERK levels were slightly reduced (Figure 2B). We observed
similar results when we interrogated the phosphorylation state
of Akt at Thr308 (data not shown). We also examined alterations
in Akt phosphorylation upon EGF stimulation in HMECs over
time. Significantly, following EGF stimulation, we observed sus-
tained levels of phosphorylated Akt in st-expressing cells (Figure
2C), while in control cells, Akt phosphorylation was maximal at
10 min and declined to basal levels 60 min after EGF stimulation
(Figure 2C). These effects of st on Akt phosphorylation in HMECs
did not depend on the presence of LT (data not shown). Thus,
expression of st permits enhanced and prolonged phosphoryla-
tion of Akt in HMECs.
st-induced HMEC transformation requires
PI3K function
To investigate whether st-induced HMEC transformation re-
quires PI3K signaling, we used a well-characterized dominant-
negative mutant of the PI3K regulatory subunit, p85, lacking
the binding site for the catalytic subunit, p110 (Dhand et al.,
1994). This mutant, designated p85, strongly inhibits PI3K-
dependent Ras-induced transformation of NIH3T3 cells (Rodri-
guez-Viciana et al., 1997). We introduced this p85 mutant or
a control vector into late passage HMECs-hTERT expressing
LT and st. The expression level of p85 in these cells was
equivalent to that of endogenous p85 (Figure 3A), and the cells
proliferated normally under standard conditions (data not
shown). However, when we tested these cells for their ability
to grow in an anchorage-independent fashion, we found that
introduction of p85 into HMECs-hTERT-LT-st abolished col-
ony formation (Figure 3B), indicating that the PI3K pathway
participates in the st-mediated transformation of human cells.
Activation of PI3K permits anchorage-independent
growth of late passage HMECs-hTERT-LT
To test the direct involvement of the PI3K pathway in the trans-
formation of HMECs, we introduced an activated allele of PI3K,
Figure 1. Anchorage-independent growth of late passage HMECs-hTERT ex-
Myr-FLAG-p110, into late passage HMECs-hTERT expressingpressing LT and st
LT. This FLAG epitope-tagged Myr-p110 is membrane-tar-A: Immunoblot analysis of cells expressing LT and/or st. Sixty micrograms of
geted and constitutively activated by N-terminal myristoylationsoluble cell lysates were separated on 10% gels and blotted with a mono-
clonal antibody (mAb) specific for the SV40 early region. (Klippel et al., 1996). The ectopically expressed Myr-FLAG-
B: Soft agar growth of late passage HMEC-hTERT expressing SV40 early p110 protein in HMECs was verified by immunoprecipitation
region, or cDNAs encoding LT and st, respectively, as indicated. 5  104
with anti-FLAG M2-agarose and immunoblotting with anti-FLAGcells were seeded per 60 mm plate, and the number of soft agar colonies
antibody (Figure 4A). Endogenous Akt proteins were phosphory-(0.2 mm in diameter) was scored after 3 weeks. The means  SD for three
experiments are shown. lated with or without EGF stimulation in HMECs expressing Myr-
FLAG-p110 (Figure 4B), confirming the constitutive activation
of Myr-FLAG-p110. Expression of Myr-FLAG-p110 in
HMECs-hTERT-LT resulted in growth of colonies in soft agar
(Figure 4C) similar to that induced by st (Figure 1B), indicating
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Figure 2. Effect of st on phosphorylation of Akt and ERK
A: Expression of st increases Akt phosphorylation. Cells were starved in MEBM overnight and then stimulated with EGF (0.1 ng/ml or 10 ng/ml) for 5 min.
Cell lysates were analyzed by immunoblotting with antibodies specific to phospho-Akt (Ser473) or total Akt. Data are presented as the percentage of Akt
phosphorylation when compared with control cells stimulated with EGF (10 ng/ml) and are the means  SD for three experiments (lower panel).
B: Expression of st decreases the ERK phosphorylation. Cells were treated as in (A), and cell lysates were analyzed by immunoblotting with antibodies
specific to phospho-ERK1/2 or total ERK1/2. Data are presented as the percentage of ERK phosphorylation when compared with control cells stimulated
with EGF (10 ng/ml). The means  SD for three experiments are shown (lower panel).
C: Expression of st prolongs EGF-induced phosphorylation of Akt. Cells were starved in MEBM overnight and stimulated with EGF (10 ng/ml) for the indicated
time periods. Cell lysates were immunoblotted with antibodies specific to phospho-Akt (Ser473) or total Akt. Data are presented as the percentage of Akt
phosphorylation when compared with control cells stimulated with EGF for 10 min (lower panel). The means  SD for three experiments are shown.
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Figure 4. Anchorage-independent growth of late passage HMECs-hTERT-LT
Figure 3. p85 inhibits the soft agar colony formation of late passage expressing Myr-FLAG-p110 or Myr-FLAG-Akt1
HMECs-hTERT-LT expressing st
A: Expression of Myr-FLAG-p110 or Myr-FLAG-Akt1 was confirmed by immu-
A: Immunoblot analysis of cells expressing p85 in the presence or absence noprecipitation with anti-FLAG M2 affinity agarose gel and immunoblotting
of st with a mAb specific for p85. with an anti-FLAG antibody.
B: Soft agar growth of HMECs-hTERT-LT expressing st is inhibited by p85. The B: Phosphorylation of Akt and ERK1/2 in cells expressing Myr-FLAG-p110 or
assay was carried out as described in Experimental Procedures, and the Myr-FLAG-Akt1 in the presence or absence of EGF stimulation. Cells were
means  SD for three experiments are shown. starved in MEBM overnight and treated with EGF (10 ng/ml) for 5 min. Cell
lysates were analyzed by immunoblotting with antibodies specific for phos-
pho-Akt (Ser473), Akt, phospho-ERK1/2, or ERK1/2. Both forms of Myr-FLAG-
Akt1 and endogenous Akt are revealed by immunoblotting with an anti-
Akt antibody. Akt is phosphorylated in cells expressing Myr-FLAG-Akt1orthat activation of PI3K substitutes for the expression of st to
Myr-FLAG-p110 independent of growth factor stimulation. Expression of
transform the late passage HMEC-hTERT-LT. Myr-FLAG-Akt1or Myr-FLAG-p110 reduced the phosphorylation level of
ERK1/2.
C: Soft agar growth of late passage HMECs-hTERT-LT expressing Myr-FLAG-Coactivation of Akt1 and Rac1 permits anchorage-
p110. Many small colonies (0.1 mm in diameter) were developed inindependent growth of late passage
cells expressing Myr-FLAG-Akt1 after 3 weeks. The means  SD for threeHMECs-hTERT-LT
experiments are shown.
PI3K signaling leads to the activation of several distinct signaling
pathways. To determine which PI3K-dependent pathways par-
CANCER CELL : MAY 2003 487
A R T I C L E
ticipate in HMEC transformation, we studied the transforming Effects of PI3K signaling on cell proliferation
In order to assess the effects of st and PI3K pathway signalingactivities of several downstream targets of PI3K. Since st ex-
on cell proliferation, we characterized the growth properties ofpression led to increased and prolonged phosphorylation of
HMEC-hTERT-LT cells stably expressing st, Myr-Flag-p110,Akt, we introduced a membrane-targeted, epitope-tagged, con-
Myr-Flag-Akt1, or Myr-Flag-Akt1 and Rac1V12. Proliferationstitutively active allele of Akt1 (Myr-FLAG-Akt1) into late passage
was determined by assessing relative cell accumulation at vari-HMEC-hTERT-LT cells (Figure 4A). This myristoylated Akt1 is
ous times post-plating (Serrano et al., 1997). In fully supple-constitutively phosphorylated regardless of the presence of
mented mammary epithelial growth medium (MEGM), each ofgrowth factors such as EGF, whereas the endogenous Akt is
these cells displayed growth rates similar to those of cells ex-only phosphorylated in the presence of EGF (Figure 4B). In
pressing the control vector (Figure 6A). However, when the cellsHMECs expressing Myr-FLAG-Akt1 or Myr-FLAG-p110, we
were maintained in culture medium supplemented with 0.5%observed downregulation of ERK1/2 phosphorylation levels
of the normal growth factors, only cells expressing st, Myr-Flag-(Figure 4B), similar to the levels seen in HMECs-hTERT express-
p110, or Myr-Flag-Akt1 and Rac1V12 were able to grow (Figureing st (Figure 2B). This observation is consistent with previous
6B). These cells were the same cells previously found to beobservations that the Raf-MEK-ERK pathway is inhibited by
capable of anchorage-independent growth. Cells expressing
activation of the PI3K/Akt pathway in C2C12 myoblasts, HEK293
control vector or Myr-Flag-Akt1 alone were unable to proliferate
cells, and MCF7 breast cancer cells (Rommel et al., 1999; Zimmer- under starved conditions (Figure 6B). These observations show
mann and Moelling, 1999). While these cells formed small colo- that transformed HMECs have reduced requirements for extra-
nies in soft agar (Figure 4C), no large colonies appeared, even cellular growth-promoting factors.
after extended incubation, indicating that while the myristoy-
lated Akt exhibits constitutive activity, it is unable to allow these c-Myc and PI3K suffice to transform early passage
HMEC cells to grow in soft agar. These observations suggest HMECs and BJ human fibroblasts in vitro
that other downstream targets of PI3K, besides Akt, are required in the presence of hTERT and LT
in concert to fully transform these HMECs. The observation that st or activation of PI3K signaling was suffi-
Rac1, a member of the Rho family of GTPases, functions cient to confer anchorage-independent growth to late passage
downstream of PI3K (Hawkins et al., 1995; Reif et al., 1996; HMEC-hTERT-LT in the absence of oncogenic Ras suggested
Welch et al., 1998). Like Akt, Rac1 can be rendered oncogenic that, with passage, these hTERT-immortalized HMECs acquired
(Rodriguez-Viciana et al., 1997; Urich et al., 1997). We tested genetic alterations that contribute to transformation. Wang et
whether Rac1 is activated in HMECs-hTERT-LT stably express- al. had previously shown that elevated levels of c-Myc occur in
hTERT-immortalized HMECs cultured for more than PD 107ing active PI3K. Cells were starved of growth factors, and Rac-
despite retaining a normal karyotype (Wang et al., 2000). Indeed,GTP, the active form of Rac, was precipitated from fresh lysates
we confirmed that the late passage HMEC-hTERT cells usedusing human PAK-1 PBD (p21 binding domain) agarose, which
in these studies express higher levels of c-Myc protein thanspecifically binds the GTP bound form of Rac (Benard et al.,
those of early passage cells (Figure 7A).1999). Using an antibody specific for active Rac1, we observed
To determine the role of c-Myc oncoprotein in human cellelevated Rac-GTP levels in HMECs expressing Myr-FLAG-
transformation, we stably introduced c-myc into early passagep110 or expressing H-rasV12 (Figure 5A), which is known to
HMEC-hTERT cells (PD 20) (Figure 7A) and subsequently intro-activate Rac (Nimnual et al., 1998; Scita et al., 1999), suggesting
duced LT and st, Myr-Flag-p110, or Myr-Flag-Akt1 andthat Rac is regulated by PI3K in HMECs. Rac-GTP levels were
Rac1V12. The serial introduction of these genes required 30not elevated in HMECs-hTERT-LT cells expressing st without
PD. These cells and all control cells were tested at PD 50 forgrowth factor stimulation (Figure 5A). Similar to the effect of st
their ability to grow in an anchorage-independent fashion. Ex-on Akt activation (Figure 2C), Rac-GTP levels were sustained
pression of st, Myr-Flag-p110, or Myr-Flag-Akt1 and Rac1V12in HMECs-hTERT-LT-st following EGF stimulation (Figure 5B),
alone failed to transform early passage HMECs-hTERT-LT.indicating that st modulates Rac as well as Akt.
However, the additional expression of c-myc or H-rasV12 into
We then investigated whether coexpression of activated
these early passage HMECs conferred the ability to grow in
Akt1 and Rac1 was sufficient for transformation. We cointro- an anchorage-independent manner (Figure 7B and data not
duced constitutively active Rac (Rac1V12) and Myr-FLAG-Akt1, shown), indicating that the elevated expression of c-myc func-
singly and in combination, into late passage HMEC-hTERT-LT tionally replaces the expression of active H-ras to promote an-
and verified the expression and activation of Rac1V12 in HMECs chorage-independent growth of HMECs.
(Figure 5A). Unfortunately, we were unable to obtain HMECs- We further tested whether activation of PI3K and overex-
hTERT-LT expressing Rac1V12 alone, perhaps in part because pression of c-myc also conferred anchorage-independent
Rho GTPases, including Rac1 and Cdc42, provoke proapoptotic growth upon another human cell type. We stably introduced
pathways through JNK signaling (Kimmelman et al., 2000), c-myc into early passage hTERT-immortalized human foreskin
which may be offset by the activation of the PI3K/Akt pathway fibroblasts (BJ) (Hahn et al., 1999) (Figure 7A), and subsequently
(Murga et al., 2002). We found that only the coexpression of introduced LT and st or Myr-Flag-p110. Similar to our observa-
Rac1V12 and Myr-FLAG-Akt1 in late passage HMEC-hTERT- tions in HMECs, we found that the combination of c-myc and
LT permitted anchorage-independent growth (Figure 5C). While st or Myr-Flag-p110 in BJ-hTERT-LT permitted colony forma-
these observations suggest that coactivation of Akt and Rac tion in soft agar (Figure 7C), suggesting that functions of PI3K
signaling may substitute for activation of PI3K to permit in vitro and c-myc in transformation are not unique to HMECs. Indeed,
HMEC transformation, they do not eliminate the critical partici- the combination of c-myc, LT, st, and hTERT also suffice to
transform another strain of human fibroblasts, LF-1 (Wei et al.,pation of other pathways downstream of PI3K.
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Figure 5. Anchorage-independent growth of
late passage HMECs-hTERT-LT coexpressing Myr-
FLAG-Akt1 and Rac1V12
A: Rac1V12 expression and Rac activation in
HMECs. Cells were starved in MEBM overnight,
and fresh cell lysates were prepared for GTP-Rac
affinity precipitation. Immunoblot assays with
anti-Rac were performed on pulldowns and cell
lysates. Rac1V12 is highly activated in the ab-
sence of any growth factor. The activation of
endogenous Rac is elevated in HMECs express-
ing Myr-FLAG-p110 and H-rasV12 without
growth factor stimulation.
B: Rac activation is sustained in HMECs express-
ing st upon EGF stimulation. Cells were starved
in MEBM overnight and treated with EGF (10 ng/
ml) for the time indicated. Fresh cell lysates were
prepared for GTP-Rac affinity precipitation. Im-
munoblot assays with anti-Rac were performed
on both pulldowns and cell lysates. Data are pre-
sented as the percentage of Rac activation
when compared with control cells stimulated
with EGF for 0.5 min (lower panel).
C: Soft agar growth of late passage HMECs-
hTERT-LT coexpressing Myr-FLAG-Akt1 and
Rac1V12. The means  SD for three experiments
are shown.
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expression to grow in soft agar, but failed to promote tumor
formation in vivo (Table 1).
Since high-level expression of H-rasV12 was required for
tumor formation of HMECs expressing hTERT, LT, and st (Elen-
baas et al., 2001), we tested whether a critical threshold level
of c-myc expression is also required for tumorigenic transforma-
tion of HMECs. Ectopically introducing c-myc into late passage
HMECs-hTERT-LT expressing st or Myr-Flag-p110 in addition
to the already elevated endogenous expression level of c-myc
also failed to permit these cells to produce tumors in animal
hosts (Table 1). The additional introduction of H-rasV12 into
these cells expressing hTERT, LT, and st or Myr-Flag-p110
promoted efficient tumor formation (Table 1). Consistent with
these findings, we noted that the cointroduction of Myr-Flag-
p110 and H-rasV12 induced higher levels of Akt phosphoryla-
tion than were observed in cells expressing either one of these
elements singly (Figure 7D). Moreover, since HMECs expressing
hTERT, LT, and H-rasV12, but lacking st or Myr-Flag-p110,
were unable to develop tumors (Table 1), these observations
indicate that, although Ras activates PI3K signaling, the intro-
duction of an activated allele of PI3K conferred additional signals
required to convert human cells into tumorigenic cells.
Discussion
Here we demonstrate that activation of the PI3K pathway plays
a crucial role in HMEC transformation. Since targets of st and
H-Ras overlap in significant ways, the observation that late
passage HMECs-hTERT expressing LT and st in the absence of
H-rasV12 are capable of anchorage-independent growth greatly
facilitated our study of the effects of st in cell transformation
by eliminating the confounding effects of oncogenic Ras. One
critical activity of st in cellular transformation is its ability to
interact with and inhibit PP2A, a family of serine/threonine phos-
Figure 6. Growth properties of HMECs-hTERT-LT expressing st, Myr-FLAG-
phatases (Mungre et al., 1994; Porras et al., 1996). As a conse-p110, Myr-FLAG-Akt1, or Myr-FLAG-Akt1 and Rac1V12
quence of PP2A inhibition by st, the phosphorylation states ofA: Cells were grown in medium supplemented with growth factors at the
many cellular kinases are altered (Janssens and Goris, 2001).concentrations suggested by the manufacturer.
B: Cells were grown in medium supplemented with a reduced (0.5%) con- Our observations indicate that the PI3K pathway plays an essen-
centration of the growth factors used in (A). tial role in the transformation of HMECs and that st perturbs
the physiological regulation of PI3K activity to facilitate cell
transformation.
Although it is clear that SV40 st perturbs PI3K signaling,
2003). Together, we conclude that in the setting of the expres- this viral oncoprotein may target the PI3K pathway at several
sion of hTERT and LT, PI3K and c-myc functionally replace st levels. Expression of st does not alter tyrosine phosphorylation
and H-rasV12 to enable human cells to grow in an anchorage- of the insulin, IGF-1, or EGF receptors (Ugi et al., 2002). A direct
independent manner. interaction between st and PI3K has not yet been demonstrated.
Expression of st failed to increase Akt phosphorylation in the
Activated PI3K replaces st for tumor growth in HMECs absence of EGF stimulation, but instead phosphorylation of
but overexpression of c-myc fails to replace Akt is increased and sustained upon EGF stimulation in st-
the requirement for H-rasV12 expressing cells. These findings are consistent with a model in
Although anchorage-independent growth often correlates with which st functions at the level of Akt (Yuan et al., 2002). In
tumorigenicity, we determined whether the introduction of PI3K contrast, the mechanism by which st affects Rac activity remains
and c-myc into HMECs conferred the ability to form tumors unknown. The results presented here are reminiscent of a recent
in animal hosts. Since mixing of human mammary fibroblasts study that showed that expression of st in MDCK cells led
(HMFs) or Matrigel provides a more physiologic microenviron- to elevated activity and expression of Rac1 and Cdc42 and
ment that abrogates the long latency and inefficient growth of disorganization of the actin cytoskeleton (Nunbhakdi-Craig et
HMEC-derived tumors (Noel et al., 1993; Elenbaas et al., 2001), al., 2003). Increasing evidence indicates that serine/threonine
we introduced HMECs expressing various combinations of on- phosphorylation of Rho/Rac guanine nucleotide exchange fac-
cogenes mixed with normal HMFs or Matrigel into immunodefi- tors (GEFs), such as Vav, Tiam-1, and PIX, are important for
cient mice. Expression of st or Myr-Flag-p110was sufficient to activation of Rac (Fleming et al., 1997; Bustelo, 2000; Shin et
al., 2002).enable late passage HMECs-hTERT-LT bearing elevated c-myc
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Figure 7. c-myc and Myr-FLAG-p110 cooperate to permit anchorage-independent growth of early passage HMECs and BJ fibroblasts expressing hTERT
and LT
A: The expression of c-Myc protein. Cell lysates were prepared from early passage HMECs-hTERT (PD 50) and BJ fibroblasts in the absence or presence of
ectopic c-myc expression and late passage cells (PD 140). The protein levels of c-Myc and actin from cells indicated were analyzed by immunoblotting.
B: Soft agar growth of early passage HMECs-hTERT-LT expressing st, Myr-FLAG-p110, or Myr-FLAG-Akt1 and Rac1V12 in the presence of c-myc. The means 
SD for three experiments are shown.
C: Soft agar growth of early passage BJ-hTERT-LT cells expressing st or Myr-FLAG-p110 in the presence of c-myc.
D: Phosphorylation of Akt in HMEC-hTERT-LT cells expressing Myr-FLAG-p110 and RasV12. Cells were starved in MEBM overnight. Cell lysates were analyzed
by immunoblotting with antibodies specific for phospho-Akt (Ser473).
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The observation that overexpresssion of c-myc failed toTable 1. Formation of subcutaneous tumors in nude mice
replace H-rasV12 for HMEC tumor formation emphasizes the
Number of tumors/injection important role of Ras signaling in tumorigenesis. Ras transfor-
mation is mediated by activation of its multiple downstreamCells with HMF with Matrigel
effector pathways. Recent work has begun to elucidate theHMEC/hTERT 0/3
specific signaling pathways perturbed by H-Ras in the transfor-HMEC/hTERT, T 0/3
HMEC/hTERT, T, t 0/6 0/3 mation of human cells. Using well-characterized Ras effector
HMEC/hTERT, T, Myr-Flag-p110 0/6 0/3 mutants, Hamad et al. reported that activation of PI3K was
HMEC/hTERT, T, t, c-Myc 0/6 0/3 not essential to transform human fibroblasts, embryonic kidneyHMEC/hTERT, T, Myr-Flag-p110, c-Myc 0/6 0/3
epithelial cells, and astrocytes (Hamad et al., 2002). In theseHMEC/hTERT, T, t, RasV12 9/9 6/6
HMEC/hTERT, T, Myr-Flag-p110, RasV12 6/6 3/3 studies, activation of the RalGDS and Raf pathways played
HMEC/hTERT, T, RasV12 0/6 0/3 prominent roles in the transformation of human and murine cells,
HMF 0/3 respectively. We believe these observations may be reconciled
For each injection, 2  106 cells of the indicated populations mixed with with the present observations since the effects of Ras on the
2  106 cells of HMF, or 4  106 cells of HMECs mixed with Matrigel, were PI3K pathway in the previous studies might have been masked
injected subcutaneously in a volume of 200 l. Mice were sacrificed when by the presence of st. Moreover, a Ras effector mutant thattumors reached a diameter of 1 to 1.2 cm or after 4 months of monitoring.
only activated RalGDS permitted anchorage-independent
growth, but failed to promote tumor formation (Hamad et al.,
2002). This notion is supported by the observation that PI3K
function was required for Ras transformation of NIH3T3 cellsOur studies indicate that activation of Akt is not necessarily
(Rodriguez-Viciana et al., 1997).synonymous with PI3K activation. Akt, a major target of PI3K,
However, several observations indicate that H-rasV12-was identified as a key regulator of cell survival and proliferation
induced stimulation of the PI3K pathway fails to provide suffi-and has been implicated in oncogenesis (Datta et al., 1999;
cient PI3K signaling for oncogenic transformation of human cellsVivanco and Sawyers, 2002). Although Akt1 activity is often
(Table 1) (Hahn et al., 2002). Since previous work has shownelevated in breast and prostate cancers (Sun et al., 2001), a
that high levels of H-rasV12 expression are required for tumorconstitutively active allele of Akt1 failed to replace active PI3K to
formation (Elenbaas et al., 2001), one possible explanation forpromote the transformation of HMECs. However, the additional
these observations is that a threshold level of PI3K signalingexpression of Rac1V12 with Myr-FLAG-Akt1 achieved efficient
is required for transformation, which cannot be provided bycolony formation in soft agar. Although we have not exhaustively
H-rasV12-induced signaling. An alternative explanation involvestested all PI3K targets for their ability to complement Akt, the
the spatial organization of activated signaling pathways. In thepathway regulated by Rac1 is an attractive candidate since
vicinity of an activated H-rasV12 molecule, multiple pathwaysRac1 is a protooncogene implicated in human cancers (Sahai
are activated, perhaps in conflict with each other. In this case,and Marshall, 2002).
expression of an activated allele of PI3K may provide the correctThe direct cooperation of PI3K and c-Myc in human cell
local environment for signaling or may counteract excessivetransformation suggests that a functional connection between
Ras-induced signaling that might lead to growth arrest (Serranothese oncogenic pathways exists. Several studies have shown
et al., 1997). Although we still do not understand the relation-that antiapoptotic proteins, such as Bcl2 and Bmi1, cooperate
ships between Ras and PI3K signaling, experimental systemsstrongly with c-Myc in tumorigenesis by inhibiting c-Myc-
such as those described herein will provide important modelsinduced apoptosis (Reed et al., 1990; Fanidi et al., 1992; Jacobs
for future studies.et al., 1999). This relationship between an antiapoptotic factor
The long-term cultivation of HMECs requires that such cellsand c-Myc also applies to PI3K/Akt and c-Myc since c-Myc-
bypass several proliferative barriers. As several groups haveinduced apoptosis can be suppressed by activation of PI3K/
reported, bypassing M0 appears to be dependent upon loss ofAkt (Kauffmann-Zeh et al., 1997). Recent studies have shown
expression of p16INK4A (Foster et al., 1998; Romanov et al., 2001),that coordination of c-Myc and PI3K is responsible for cell cycle
although conditions may exist that permit long-term cell growthprogression in fibroblasts (Jones and Kazlauskas, 2001). Simi-
without loss of p16INK4A (Herbert et al., 2002). Moreover, thelarly, in Drosophila, an activated form of Ras has been shown
further introduction of LT and hTERT permitted these HMECsto promote cell growth and G1/S progression by increasing Myc
to bypass replicative senescence. Since the upregulation ofand activating PI3K signaling (Prober and Edgar, 2002).
c-Myc appears to be a common feature of late passage hTERT-Is the observation that elevated c-Myc expression can func-
immortalized HMECs (Wang et al., 2000; Elenbaas et al., 2001),tionally substitute for oncogenic H-Ras in the anchorage-inde-
it remains possible that such late passage HMECs also harborpendent growth of hTERT-immortalized HMECs indicative of a
other genetic alterations. However, since the introduction ofmechanistic tie between Ras activation and Myc expression?
c-Myc into early passage HMECs recapitulated the transforma-Previous studies of HMEC transformation have noted that ampli-
tion phenotypes of late passage HMECs (Figure 7), we concludedfication of c-myc occurred during the introduction of the SV40
that it is unlikely that other cooperating genetic events in lateearly region, hTERT, and H-rasV12 into early passage HMECs
passage HMECs contribute to the HMEC transformation ob-(Elenbaas et al., 2001). Similarly, c-myc can replace H-rasV12
served here.in the transformation of human fibroblasts in combination with
Although transformed cells that acquire the capability tohTERT, SV40 LT, and st (Wei et al., 2003). Since Ras signaling
grow in an anchorage-independent manner usually also formenhances the accumulation of c-Myc protein via inhibition of
tumors in animal hosts (Cifone and Fidler, 1980), we found thatproteasome-mediated degradation (Sears et al., 2000), one con-
sequence of Ras signaling is to elevate Myc levels. some combinations of introduced genes confer only anchorage-
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branes were blocked and probed with the specified antibodies; namely,independent growth while others impart a full tumorigenic phe-
anti-phospho-Akt (Ser473 or Thr308), anti-Akt, anti-phospho-p44/42 MAPKnotype. While the reasons for this difference in behavior remain
(Thr202/Tyr204), anti-p44/42 MAPK (all from Cell Signaling Technology),unknown, these observations indicate that tumorigenic cells
anti-c-Myc (sc-764, Santa Cruz), anti-p85 (UB93-3, Upstate Biotechnology),
acquire one or more functional capabilities beyond that required anti-FLAG M2 (Sigma), anti-Actin (Sigma), anti-Rac (clone 23A8, Upstate
for anchorage-independent growth. Identifying and understand- Biotechnology), and PAb419 mAb specific for SV40 T antigens (Harlow et
ing these additional steps will elucidate critical steps in cancer al., 1981) were used throughout.
development.
Rac activation assayIn summary, we have identified the PI3K pathway as a critical
Cells were grown until 70% confluent, then starved overnight in MEBM.signaling pathway targeted by st for the transformation of
For the timecourse experiments, cells were treated with EGF (10 ng/ml) for
HMECs-hTERT. These observations have made it possible to the times indicated. Fresh cell lysates were prepared and subjected to Rac
create human cells whose transformation is critically dependent activation assay using Rac Activation Assay Kit (Upstate Biotechnology)
upon PI3K, Akt, and Rac expression and will allow us to con- according to the manufacturer’s instructions.
struct more relevant models of human breast cancer. In addition,
Growth curvesthese experimental models will provide a useful platform for the
HMECs were plated at a density of 2.5  104 per well in 12-well plates. Attesting and development of specific inhibitors of these onco-
the indicated time points, cells were washed with PBS, fixed in 10% formalin,genic pathways.
and rinsed with distilled H2O. Cells were then stained with 0.1% crystal violet
(Sigma) for 30 min, washed with distilled H2O, and dried. Cell-associatedExperimental procedures
dye was extracted with 2 ml of 10% acetic acid, and the optical density
was measured at 590 nm. Values were normalized to the OD590 at day 0 forVectors and retrovirus production
each cell type. Each point was determined in triplicate. For experiments
The SV40 early region was introduced into the pWZL-blast retroviral vector
performed with limited supplementation, MEBM was augmented with 0.5%
(a gift from J. Morgenstern, Millennium Pharmaceuticals). cDNA versions of
of the standard growth factor concentrations.
SV40 LT or st were cloned into pBabe-puro (Morgenstern and Land, 1990)
and pWZL-blast, respectively. Myc-tagged Rac1V12 (Ridley et al., 1992)
Anchorage-independent growth assay
was cloned into pWZL-neo. pBabe-puro carrying human c-myc was kindly
5  104 HMECs were seeded per 60 mm plate with a bottom layer of 0.6%
provided by M. Eilers, and this cDNA was also introduced into pBabe-zeo.
Bacto agar in DMEM and a top layer of 0.3% Bacto agar containing MEGM.
The amino-terminal ends of p110 and Akt1 were modified by the pp60
Fresh MEGM (0.5 ml) was added after 1.5 weeks. Growth of BJ fibroblasts
c-Src myristoylation sequence (Klippel et al., 1996) and fused in frame with
in soft agar was performed as previously described (Hahn et al., 1999).
FLAG-epitope tag. Myr-FLAG-p110 and Myr-FLAG-Akt1 were cloned into
Colonies were scored after 3 weeks. Only those colonies with greater than
pWZL-neo and pWZL-blast retroviral vectors, respectively. The p85iSH2
0.2 mm in diameter were counted. Such colonies are visible without micros-
(deletion of amino acids 478-513) (Dhand et al., 1994) cDNA was subcloned
copy and typically contain 50–60 cells. At least two independent assays
into pWZL-neo.
were performed in triplicate.
Amphotropic retroviruses were produced by transfection of the 293
cells with packaging plasmids encoding VSV-G, gag-pol, and a retroviral
Tumorigenicity assaysvector encoding the gene of interest. Culture supernatants containing retrovi-
six- to eight-week-old immunocompromised mice (Cby.Cg-Foxn1nu, Jack-rus were collected 48 hr posttransfection.
son Laboratory) were -irradiated (400) rad prior to injection. HMECs cells
(2  106 ) resuspended in 100 l of PBS were mixed with HMF cells (2 Cell culture
106 ) resuspended in 100 l of PBS and injected subcutaneously. For MatrigelEarly and late passage HMECs-hTERT (Clontech) were cultured in mammary
(Becton Dickinson) injections, HMEC cells (4  106 ) were resuspended inepithelial basal medium (MEBM, BioWhittaker) supplemented with EGF, in-
100 l of PBS and 100 l of Matrigel. Tumor size was monitored every 5sulin, bovine pituitary extract, and hydrocortisone (termed mammary epithe-
days. Mice were sacrificed when the tumors reached a diameter of 1 cmlial growth medium, MEGM) at 37	C and 5% CO2 according to the manufac-
or after 16 weeks of monitoring.turer’s instructions (BioWhittiker). BJ human foreskin fibroblasts were
maintained in a 4:1 mixture of Dulbecco modified Eagle medium to M199
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